Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences entered an underwriting agreement for an underwritten public offering of 735,000 shares of common stock at $6.12 per share. The company estimates approximately $3.9 million in net proceeds, to be used for working capital, general corporate purposes, and advancement of its DNase technology.
The offering is being conducted under Xenetic’s effective Form S-3 shelf registration statement (File No. 333-282756). The company agreed to a 60-day restriction on issuing or selling additional common stock or convertible securities following the agreement date. Canaccord Genuity LLC is the representative of the underwriters.
Xenetic Biosciences launched a primary offering of 735,000 shares of common stock at $6.12 per share, for $4,498,200 in gross proceeds. The underwritten deal, led by Canaccord Genuity, carries an underwriting discount of $0.3672 per share, with proceeds to the company before expenses of $4,228,308 and estimated net proceeds of approximately $3.9 million after offering expenses.
The company plans to use the funds for working capital, general corporate purposes, and to advance its DNase immuno‑oncology technology. Shares outstanding were 1,542,139 prior to the offering and are expected to be 2,277,139 after. Officers and directors agreed to 60‑day lock‑ups. Delivery of shares is expected on or about October 14, 2025. As of October 9, 2025, public float was cited under Form S‑3 I.B.6, and the company noted it had not sold securities under I.B.6 in the prior 12 months.
The filing also discloses a formal strategic review evaluating alternatives, including a potential sale, asset sale, or reverse merger, with no set timetable and no assurance of completion.
Xenetic Biosciences, Inc. filed a prospectus supplement for a public offering that would increase its common stock outstanding beyond the 1,542,139 shares reported as of October 9, 2025. The supplement discloses convertible and exerciseable instruments that could add roughly 0.3 million common-share equivalents: ~0.1M from Series B Preferred conversion, ~0.1M potentially from milestone payments, and ~0.1M from outstanding options, plus 834 shares issuable on warrants.
The filing names Canaccord Genuity LLC as an underwriter and estimates offering expenses payable by the company (excluding underwriting discounts) of approximately $0.2M. It highlights extensive risk factors tied to the DNase technology development, funding needs and potential inability to maintain Nasdaq listing standards, and lists customary securities terms and distribution/resale restrictions across multiple jurisdictions.
Xenetic Biosciences, Inc. reported that it issued a press release with its financial results for the three months ended June 30, 2025. The company furnished this press release as an exhibit to a current report, making the quarter’s performance details available to investors through that document.
The disclosure also includes an extensive caution about forward-looking statements, noting that expectations are subject to numerous risks and uncertainties described in Xenetic’s other SEC reports. The company’s common stock continues to trade on The Nasdaq Stock Market under the symbol XBIO.
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.